+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hormone Replacement Therapy (HRT): Global Strategic Business Report

  • PDF Icon

    Report

  • 276 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1946783

Global Hormone Replacement Therapy (HRT) Market to Reach $40.1 Billion by 2030

The global market for Hormone Replacement Therapy (HRT) estimated at US$24.5 Billion in the year 2022, is projected to reach a revised size of US$40.1 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2022-2030. Estrogen Hormone Replacement Therapy, one of the segments analyzed in the report, is projected to record a 6.4% CAGR and reach US$21.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Human Growth Hormone Replacement Therapy segment is readjusted to a revised 7.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $7.2 Billion, While China is Forecast to Grow at 5.9% CAGR

The Hormone Replacement Therapy (HRT) market in the U.S. is estimated at US$7.2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$7 Billion by the year 2030 trailing a CAGR of 5.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Allergan Plc
  • Bayer AG
  • Novartis AG
  • Noven Pharmaceuticals Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • TherapeuticsMD Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • An Introduction to Menopause and Hormone Replacement Therapy
  • Recent Market Activity
  • The HRT Controversy - An Insight
  • Newer Studies Challenge WHI Findings and Re-establish Safety of HRT
  • Revised Recommendations of the NAMS and Endocrine Society
  • IMS Consensus Guidelines Paving Way for More Clarity of HRT
  • The Regional Divide
  • Increasing Number of Menopausal Women - A Major Market Driver
  • New Bioidentical Drugs Serve Unmet Market Needs
  • Generic Incursion in Hormone Replacement Therapy - List of Drugs With and Without Approved Generic Versions
  • Intense Competition Marks the Global HRT Market
  • The Premarin Saga
  • Estrace Cream Drives Revenue Gains in Allergan’s HRT Portfolio
  • Hormone Replacement Therapy (HRT) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
  • Abbott Laboratories (USA)
  • Allergan Plc (Ireland)
  • Bayer AG (Germany)
  • Noven Pharmaceuticals, Inc. (USA)
  • Novartis AG(Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Orion Pharma AB (Finland)
  • Pfizer, Inc. (USA)
  • TherapeuticsMD, Inc. (USA)
3. MARKET TRENDS & DRIVERS
  • Unmet Needs in Combination Therapies for HRT drive Research for New Medicines
  • Topical Estrogens - More Safe and Effective
  • Transdermal HRT Products Present Exciting Opportunities
  • Phytoestrogens - The New Panacea for Menopausal Symptoms?
  • Diet Link to Menopause Symptoms Raises Interest
  • Impact of Soy and Other Phytoestrogens - A Reality Check
  • EstroG - A Successful Herbal Health Supplement in Alleviating Menopausal Symptoms
  • The Growing Buzz around Bioidentical Drugs
  • Bio-identical Hormones - A Natural and Safe Substitute to Synthetic HRT?
  • Pellet Therapy - A New Innovation Downsizes Conventional Issues with Bioidentical HRT
  • Direct-to-Consumer Advertising for HRT - A Mixed Bag
  • Estriol: The Next Generation Estrogen Therapy?
  • What Makes Estriol Work?
  • Topical Estriol - More Promising in Safety
  • Estriol - Used More Commonly Outside the US
  • Entry of Generics Threatens Market Growth Prospects
  • Are Non-Hormonal Therapies A Threat to HRT?
  • Earlier Failures Induce Lethargy in Non-Hormonal Therapies
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Hormone Replacement Therapy (HRT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Hormone Replacement Therapy (HRT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Hormone Replacement Therapy (HRT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Estrogen Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Estrogen Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Estrogen Hormone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Human Growth Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Human Growth Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Human Growth Hormone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Testosterone Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Testosterone Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Testosterone Hormone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Thyroid Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Thyroid Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Thyroid Hormone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Menopause by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Menopause by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 18: World 18-Year Perspective for Menopause by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 21: World 18-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 24: World 18-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Hypothyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 27: World 18-Year Perspective for Hypothyroidism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 28: World Recent Past, Current & Future Analysis for Other Type of Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 29: World Historic Review for Other Type of Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 30: World 18-Year Perspective for Other Type of Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 31: World Hormone Replacement Therapy (HRT) Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
CANADA
JAPAN
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
CHINA
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
EUROPE
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
FRANCE
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
GERMANY
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
ITALY
UNITED KINGDOM
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Hormone Replacement Therapy (HRT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Allergan Plc
  • Bayer AG
  • Novartis AG
  • Noven Pharmaceuticals Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • TherapeuticsMD Inc.

Table Information